ACC Highlighted Late-Breaking Trials Announced

Latest clinical trial data will be presented at ACC.13 meeting in March

 

January 25, 2013

January 25, 2013 — The American College of Cardiology (ACC) has released the late-breaking clinical trials that will be highlighted as the cutting edge of cardiology at the ACC.13 annual meeting March 9-11 in San Francisco. 

 
Opening Showcase and Late-Breaking Clinical Trials

Session 300, Saturday, March 9, 8–10 a.m., South, Esplanade Ballroom:
 
• Final Results of Randomized Trial of Left Atrial Appendage Closure Versus Warfarin for Stroke/Thromboembolic Prevention in Patients With Non-Valvular Atrial Fibrillation (PREVAIL)
 
• HPS2-THRIVE: Randomized Comparison Of Extended-Release (ER) Niacin/Laropiprant 2 g Daily Versus Placebo in 25,673 Patients At High Risk Of Occlusive Vascular Events
 
 
Late-Breaking Clinical Trials II: Interventional
Session 301, Sunday, March 10, 8–9:30 a.m., South, Esplanade Ballroom:
 
• Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome
 
• A Randomized Evaluation of the SAPIEN XT Transcatheter Valve System in Patients with Aortic Stenosis who are not Candidates for Surgery: PARTNER 2, Cohort B Outcomes
 
• One-year Outcome of a Trial Comparing Second Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: the NOBORITM Biolimus-Eluting versus Xience/Promus Everolimus-Eluting Stent Trial (NEXT)
 
• Comparison of DK Crush Versus Culotte Stenting for Unprotected Distal Left Main Bifurcation Lesions: Results from a Multicenter, Randomized, Prospective DKCRUSH-III study
 
• The Main Results of the CHAMPION PHOENIX Trial — A Comparison of Efficacy and Safety of Cangrelor to Standard of Care in Patients Requiring Percutaneous Coronary Intervention (PCI)
 
 
Late-Breaking Clinical Trials III: Chronic CAD/Stable Ischemic Heart Disease and Acute Coronary Syndromes

Session 302, Sunday, March 10, 10:45 a.m. — 12:15 p.m., South, Esplanade Ballroom:
 
• The STREAM Trial, Enoxaparin compared to Unfractionated Heparin in Myocardial Infarction Patients Undergoing PCI
 
• Early Administration of Eplerenone in Patients With Acute Myocardial Infarction Without Heart Failure: Results of the Randomized, Double-Blind, Placebo-Controlled REMINDER Trial
 
• Effects of the P-Selectin Antagonist Inclacumab in the Select-Acute Coronary Syndromes Trial
 
• Randomized Comparison of High-Dose Oral Vitamins vs. Placebo in the Trial to Assess Chelation Therapy
 
• Evaluation of  Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina: Results From the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Randomized Clinical Trial
 
 
Late-Breaking Clinical Trials IV: General Cardiology

Session 303, Monday, March 11, 8–9:30 a.m., South, Esplanade Ballroom: 
 
• Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis
 
• A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery On-Site and Community Hospitals Without Cardiac Surgery On-Site
 
• The German Off-Pump Coronary Artery Bypass Grafting in Elderly Patients (GOPCABE) Study
 
• CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 year
 
• PRAGUE-6 Trial: Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery in Patients With EuroSCORE ≥6
 
 
Late-Breaking Clinical Trials V: Heart Failure 

Session 304, Monday, March 11, 10:45 a.m. – 12:15 p.m., South, Esplanade Ballroom: 
 
• The St Vincent’s Screening To Prevent Heart Failure Study: Impact of Natriuretic Peptide Guided Screening and Treatment on Long-Term Prevalence of Left Ventricular Dysfunction, Heart Failure and Cardiovascular Events
 
• Digoxin Reduces 30-Day All-Cause Hospital Admission in Ambulatory Older Patients With Chronic Heart Failure and Reduced Ejection Fraction
 
• The ASTRONAUT Study: Aliskiren Trial On Acute Heart Failure Outcomes
 
• Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Trial
 
 
For more information:  accscientificsession.cardiosource.org